Global Plasma Fractionation Market to Reach $36.7 Billion by 2030
The global market for Plasma Fractionation estimated at US$24.1 Billion in the year 2022, is projected to reach a revised size of US$36.7 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2022-2030. Immunoglobulins, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$13.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Albumin segment is readjusted to a revised 4.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $7 Billion, While China is Forecast to Grow at 5% CAGR
The Plasma Fractionation market in the U.S. is estimated at US$7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.Select Competitors (Total 47 Featured) -
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Green Cross Corporation
- Grifols SA
- Japan Blood Products Organization
- Kedrion SpA
- LFB SA
- Octapharma AG
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Green Cross Corporation
- Grifols SA
- Japan Blood Products Organization
- Kedrion SpA
- LFB SA
- Octapharma AG
- Sanquin
- Shanghai RAAS Blood Products Co., Ltd.
- Shire PLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 197 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 24.1 Billion |
Forecasted Market Value ( USD | $ 36.7 Billion |
Compound Annual Growth Rate | 5.4% |
Regions Covered | Global |